MetLife stock has delivered a 75.8% gain over the last five years, yet the latest valuation checks send a mixed message, with the Excess Returns intrinsic value estimate pointing to a large gap to the current price while the earnings multiples look roughly in line with the market.

• A 75.8% total return over five years suggests MetLife has already rewarded patient shareholders, so fresh buyers need to think carefully about what is now priced in.
• On the positive side, steady insurance cash flows and capital return capacity can support the intrinsic value estimate. However, claims volatility and interest rate swings may weigh on how much of that value the market is willing to pay for.
• MetLife scores just 2 out of 6 on our valuation checks, which leans more toward a stock that is not a clear bargain once the broader metrics are considered.

The issue now is whether the 44.9% discount implied by the Excess Returns model is a genuine opportunity in MetLife or simply reflects risks that the simple valuation score is already hinting at.

Is MetLife a Bargain on Excess Returns?

The Excess Returns model looks at how much value MetLife creates above its estimated cost of equity. For MetLife, the inputs are anchored in a Book Value of $43.03 per share and a Stable EPS estimate of $8.45 per share. Analysts expect an Average Return on Equity of 15.78%, while the model applies a Cost of Equity of $4.02 per share. That leaves an Excess Return of $4.43 per share, which is then capitalised over time to estimate what the stock could be worth.

Using a Stable Book Value of $53.54 per share, the Excess Returns framework arrives at an intrinsic value of about $169.60 per share, which is well above the current share price. This gap implies MetLife screens as 44.9% undervalued on this model. The inputs assume the company can sustain returns on equity meaningfully above its cost of equity over the long term, which is consistent with a mature insurer with sizeable equity capital and earnings power.

On this Excess Returns view, MetLife stock looks undervalued relative to the cash it is expected to generate for shareholders over time.

Our Excess Returns analysis suggests MetLife is undervalued by 44.9%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Does MetLife Look Fairly Valued on Earnings?

P/E is a sensible way to look at MetLife because earnings are a key focus for investors in large, mature insurers. MetLife currently trades on a P/E of 17.3x, compared with an Insurance sector average of 11.0x and a peer group average of 14.4x. That points to a premium against both the wider industry and closer peers.

The fair P/E that accounts for MetLife’s size, risk profile and analyst expectations is 16.0x, only slightly below the current multiple. The gap is not large, particularly given the company’s established position and the earnings profile that supports the Excess Returns valuation work above. On this P/E view, MetLife stock does not appear to be a clear bargain or aggressively priced relative to what the model suggests investors might typically pay.

Overall, MetLife appears roughly fairly valued on its P/E multiple compared with what the tailored fair ratio implies.

The MetLife Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the valuation puzzle for MetLife leaves off and spell out what growth, margin and earnings paths would need to hold for the stock to be worth materially more or less than today’s price on the Community page. Each narrative links its number to a clear view of how MetLife's growth, profitability and risks might evolve, which you can revisit as fresh results and news come through.

You can add your voice to the Simply Wall St community by sharing a number driven Narrative on MetLife that sets out your view on where its growth, margins and execution go from here. Put a clear valuation case on MetLife today and see how it holds up as fresh data and company updates arrive.

Do you think there's more to the story for MetLife? Head over to our Community to see what others are saying!

The Bottom Line

For MetLife, the Excess Returns intrinsic value estimate points to a meaningful discount, while the P/E view suggests the stock is priced roughly in line with what similar insurers trade on. That split comes from the intrinsic model leaning on long term cash generation and capital returns, while the market multiple is more anchored in current sentiment and earnings expectations. Broader valuation checks remain weak, so the intrinsic value signal needs to be treated with care. The key question from here is whether MetLife can keep turning its equity base into cash flows that justify both the modelled upside and the current market premium on earnings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.